In addition, although missense mutations in MDM2 are rare, multiple isoforms of MDM2 protein generated by alternative promoters and alternative proteins have been observed, and the change in the sequence may disrupt the N-terminal p53-binding domain to reduce the efficacy of MDM2 inhibitors and promote tumor progression [100–103]. This evidence concerns the gene TP53 and neoplasm.